Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,603 | 7 | 97.2% |
| Food and Beverage | $151.14 | 3 | 2.2% |
| Travel and Lodging | $38.89 | 1 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $5,014 | 8 | $0 (2024) |
| GENZYME CORPORATION | $1,728 | 1 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $28.36 | 1 | $0 (2023) |
| Genmab U.S., Inc. | $22.78 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $772.78 | 2 | Janssen Biotech, Inc. ($750.00) |
| 2023 | $4,292 | 8 | Janssen Biotech, Inc. ($4,264) |
| 2021 | $1,728 | 1 | GENZYME CORPORATION ($1,728) |
All Payment Transactions
11 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Oncology | ||||||
| 02/09/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Oncology | ||||||
| 12/20/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Travel and Lodging | Cash or cash equivalent | $38.89 | General |
| Category: Oncology | ||||||
| 11/03/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Oncology | ||||||
| 10/13/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: Oncology | ||||||
| 06/02/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: ONCOLOGY | ||||||
| 04/11/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: Oncology | ||||||
| 04/11/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: Oncology | ||||||
| 10/18/2021 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $1,728.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 261 | 415 | $353,864 | $47,188 |
| 2022 | 5 | 233 | 469 | $371,455 | $52,249 |
| 2021 | 3 | 122 | 259 | $200,616 | $32,881 |
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 125 | 258 | $199,434 | $31,574 | 15.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 54 | 54 | $58,590 | $8,008 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 44 | 64 | $36,928 | $4,953 | 13.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 38 | 39 | $58,912 | $2,653 | 4.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 88 | 245 | $189,385 | $30,025 | 15.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 28 | 95 | $52,345 | $8,599 | 16.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 57 | 57 | $61,845 | $8,502 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 29 | 40 | $23,080 | $2,940 | 12.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 31 | 32 | $44,800 | $2,183 | 4.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 46 | 133 | $102,809 | $17,306 | 16.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 55 | 55 | $59,675 | $9,018 | 15.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 71 | $38,132 | $6,556 | 17.2% |
About Alfred Chung
Alfred Chung is a Hematology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2014. The National Provider Identifier (NPI) number assigned to this provider is 1417375627.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Alfred Chung has received a total of $6,793 in payments from pharmaceutical and medical device companies, with $772.78 received in 2024. These payments were reported across 11 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($6,603).
As a Medicare-enrolled provider, Chung has provided services to 616 Medicare beneficiaries, totaling 1,143 services with total Medicare billing of $132,318. Data is available for 3 years (2021–2023), covering 12 distinct procedure/service records.
Practice Information
- Specialty Hematology
- Location San Francisco, CA
- Active Since 04/03/2014
- Last Updated 03/03/2021
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1417375627
Products in Payments
- DARZALEX (Biological) $5,014
- SARCLISA (Biological) $1,728
- EPKINLY (Drug) $28.36
- Epkinly (Drug) $22.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in San Francisco
Dr. Thomas Martin, Md, MD
Hematology — Payments: $128,592
Ms. Gallia Levy, Md, Phd, MD, PHD
Hematology — Payments: $38,054
Karthik Ganapathi, Md, Phd, MD, PHD
Hematology — Payments: $27,997
Dr. Katherine Matthay, M.d, M.D
Hematology — Payments: $14,481
Dr. Scott Kogan, M.d, M.D
Hematology — Payments: $10,253
Dr. Chuanyi Lu, M.d, M.D
Hematology — Payments: $7,309